Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis

Microalbuminuria: A parameter that has changed diabetes care

(2015) Hans-Henrik Parving et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis

(2013) Jorge L. Gross   ANNALS OF INTERNAL MEDICINE

Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial

(2013) V. Fonseca et al.   DIABETES CARE

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

(2013) R. G. Moses et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

(2013) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety of Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Insufficiently Controlled with Metformin and a Sulfonylurea

(2013) Sung-Chen Liu et al.   Endocrine Practice

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

(2013) J. P. H. Wilding et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Evaluation of inconsistency in networks of interventions

(2013) A. A. Veroniki et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Network meta-analysis, electrical networks and graph theory

(2012) Gerta Rücker   Research Synthesis Methods

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

(2011) D. R. Owens et al.   DIABETIC MEDICINE

Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2

(2011) David C. Hoaglin et al.   VALUE IN HEALTH

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Earlier triple therapy with pioglitazone in patients with type 2 diabetes

(2009) G. Charpentier et al.   DIABETES OBESITY & METABOLISM

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Fate of the beta-cell in the pathophysiology of type 2 diabetes

(2009) R. Keith Campbell   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus

(2009) Nikolaos P.E. Kadoglou et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus

(2008) N. P. E. Kadoglou et al.   DIABETIC MEDICINE